Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Conference Call Tomorrow ...

<< Previous

Bullboard Posts

Next >>

Comment by GameChangerBeton Jun 23, 2021 9:21am

168 Views

Post# 33433490

RE:RE:Conference Call Tomorrow ...

No new material from what I heard.
Although reassuring of all the material positives in the near-intermmediate term.

themagicbox wrote: were you able to catch it any details? It just ended.

MrMugsy wrote: Raymond James tomorrow at 8:40 AM.

Based on the Bear Creek call today - sounds like a few things might be made a little clearer tomorrow (from what others are saying).

Someone remind Yukon not to take my advice ... he's too good to take that call anyway.

: )